Research Topics
| Luanne MetzSummaryAffiliation: University of Calgary Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)Jacqueline Bakker
Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
Can J Neurol Sci 31:265-7. 2004..These cases suggest that IVIG may be effective in preventing attacks and possibly in enhancing neurological recovery. Randomized controlled trials will be needed to confirm this and to determine optimal dosing and treatment duration...- Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?Luanne Metz
Department of Clinical Neurosciences, Foothills Medical Center, Alberta, T2N 2T9, Calgary, Canada
Lancet 362:1513. 2003 
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trialL M Metz
Department of Clinical Neuroscience, University of Calgary, Calgary, Alberta, Canada
Mult Scler 15:1183-94. 2009..We conclude that efficacy endpoints showed a consistent trend favoring combination treatment. As minocycline is a relatively safe oral therapy, further study of this combination is warranted in relapsing-remitting multiple sclerosis...
The effect of immunomodulatory treatment on multiple sclerosis fatigueL M Metz
Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
J Neurol Neurosurg Psychiatry 75:1045-7. 2004..To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis...- Disease management for depression in an MS clinicScott B Patten
Department of Community Health Sciences, University of Calgary, AB, Canada
Int J Psychiatry Med 37:459-73. 2007..We explored the feasibility and effectiveness of implementing a disease management program for depression in an MS clinic... - Corpus callosum volume and interhemispheric transfer in multiple sclerosisL N Brown
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
Can J Neurol Sci 37:615-9. 2010..Judgments to bimanual stimulations require interhemispheric transfer via the CC... - Experimental models of neuroprotection relevant to multiple sclerosisV W Yong
Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
Neurology 68:S32-7; discussion S43-54. 2007..Further studies are needed to establish whether experimental neuroprotection strategies involving these mechanisms may be translated into preventing neurodegeneration in multiple sclerosis... - Identifying reliable change in tactile temporal thresholds in multiple sclerosis: test-retest reliabilityL N Brown
Department of Psychology, University of Calgary, Calgary, Alberta, Canada
Mult Scler 12:573-7. 2006..As part of an ongoing validation study of tactile temporal thresholds, the test-retest reliability of these thresholds was examined in patients with MS... - Tactile temporal thresholds detect relapse-related changes in multiple sclerosis: a preliminary studyL N Brown
Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
Mult Scler 11:725-7. 2005..Thus, tactile temporal thresholds may be a useful outcome measure in MS. Our objective was to assess whether tactile temporal thresholds reflect change during a MS relapse... - Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosisS B Patten
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada T2N 4N1
Mult Scler 14:406-11. 2008..This is surprising since interferons used in other clinical contexts are considered capable of causing depression. The negative results in MS could be due inadequate power in the published trials... - Major depression in multiple sclerosis: a population-based perspectiveS B Patten
Department of Community Health Sciences, University of Calgary, Alberta, Canada
Neurology 61:1524-7. 2003..To determine the prevalence of major depression in multiple sclerosis (MS) in a population-based sample controlling for nonspecific illness effects... - 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot studyY Zhang
Department of Clinical Neurosciences, University of Calgary, Canada
J Neurol Sci 297:76-81. 2010..Further studies are required to confirm these results in a large sample and to determine if T2 hypointensity changes in clinically active MS patients... - The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot studyR K Zabad
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
Mult Scler 13:517-26. 2007..The activity of matrix metalloproteinase-9 was decreased by treatment. Thus, clinical and MRI outcomes are supported by systemic immunological changes and call for further investigation of minocycline in MS... - Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trialS B Patten
Department of Community Health Sciences, University of Calgary, Alberta, Canada
Mult Scler 7:243-8. 2001..6%. However, no evidence of increased depressive symptomatology was observed in association with interferon beta-1a (Rebif)... - Short term predictors of unemployment in multiple sclerosis patientsK D Busche
Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
Can J Neurol Sci 30:137-42. 2003..5 years. They should be considered for interventions to maintain employment or to lessen the impact of unemployment... - Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosisS Chabot
Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Alberta, Canada
Mult Scler 8:299-306. 2002..The net result of a non-inflammatory milieu within the CNS, in spite of T cell infiltration, may help account for the amelioration of disease activity in MS patients on glatiramer acetate therapy... - The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosisS A Morrow
Department of Clinical Neurosciences, University of Western Ontario, London, Ontario, Canada
Neurology 63:1079-80. 2004..122). This suggests that the amount of absorbed corticosteroid is similar after either steroid at these doses... - High dose oral steroids commonly used to treat relapses in Canadian MS clinicsS A Morrow
Department of Clinical Neurosciences, University of Western Ontario, London, Ontario, Canada
Can J Neurol Sci 36:213-5. 2009..Recent studies support similarities in the bioequivalence and in the clinical effect of high dose oral corticosteroids for MS relapses... - Reliability of visual temporal thresholdsL N Brown
Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada
Can J Neurol Sci 34:433-7. 2007..measurements of the temporal aspects in visual processing) are typically significantly higher (i.e., prolonged) in MS patients when compared to controls. The test-retest reliability of these thresholds was examined in patients with MS... - Deep grey matter "black T2" on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosisY Zhang
Department of Radiology, University of Calgary, Calgary, Canada
Mult Scler 13:880-3. 2007..5, P < 0.05). BT2 at 3 T may be a useful MRI measure associated with disability in MS and warrants further study... - Retinal nerve fiber layer and future risk of multiple sclerosisFiona Costello
Hotchkiss Brain Institute, University of Calgary, Department of Clinical Neurosciences, Calgary, Alberta, Canada
Can J Neurol Sci 35:482-7. 2008..The purpose of this study was to determine whether RNFL measurements obtained within two years of an optic neuritis (ON) event distinguish patients at increased risk of developing clinically-definite MS (CDMS)... - Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatmentRupang Pandya
Psychiatry Administration, Department of Psychiatry, University of Calgary, 1403 29th St, NW, Calgary, ALB T3H 2R9, Canada
Psychosomatics 46:131-4. 2005..5% (N=38) were found to have a depressive disorder. The results of the study indicate that case-finding for depressive disorders among multiple sclerosis patients can be facilitated by use of the CES-D scale... - Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesionsJian Qiang Lu
Department of Pathology and Laboratory Medicine, University of Calgary, Alberta, Canada
J Neuropathol Exp Neurol 68:179-89. 2009..The results suggest that alpha-synuclein expression regulated by inflammatory signals may contribute to neurodegenerative processes in MS lesions... - Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantationJian Qiang Lu
Department of Pathology, Foothills Medical Centre, University of Calgary, 1403 29th St NW, Calgary, Alberta T2N 2T9, Canada
Arch Neurol 66:116-20. 2009..To examine the effect of allogeneic hematopoietic cell transplantation (HCT) on disease activity in a patient with multiple sclerosis (MS)... - Cannabis use as described by people with multiple sclerosisS A Page
Office of Medical Bioethics, University of Calgary, Calgary, AB, Canada
Can J Neurol Sci 30:201-5. 2003..CONCLUSIONS: Subjective improvements in symptom experience were reported by the majority of people with MS who currently use cannabis. Further evaluation of this substance is warranted... - Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosisJ B Johnston
Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
Ann Neurol 49:650-8. 2001..Reduction of the A1AR-beta transcript in MS patients suggests that dysregulated splicing may influence A1AR protein levels, potentially leading to increased macrophage activation and central nervous system inflammation... - Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman
Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
Neurology 71:1134-41. 2008..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)... - Glatiramer acetate therapy for multiple sclerosis: a reviewJai Perumal
Wayne State University School of Medicine, Department of Neurology, 8D-UHC, Detroit, MI 48201, USA
Expert Opin Drug Metab Toxicol 2:1019-29. 2006.... - Time for a population based approach to multiple sclerosis careLuanne Metz
Can J Neurol Sci 34:120. 2007 - Corticosteroids for multiple sclerosis: I. Application for treating exacerbationsElliot M Frohman
Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235, USA
Neurotherapeutics 4:618-26. 2007..This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients... - Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisGavin Giovannoni
Neuroimmunology Unit, Institute of Cell and Molecular Science, Queen Mary University London, London, United Kingdom
Clin Ther 29:1128-45. 2007..It was developed with the aim of maximizing the treatment benefit for patients with multiple sclerosis (MS) by improving injection tolerability and reducing the development of neutralizing antibodies (NAbs)...